-
Individualization of therapy with pharmacogenetics; the rate vs rhythm debate; the FDA's Risk Evaluation and Mitigation Strategy; FDA actions.
-
-
In light of an increasing internationally mobile community, the primary care physician may see patients who have recently traveled overseas. This article highlights the manifestations of diseases that, although we may not see them often, can fool us with confusing symptoms.
-
-
-
To incorporate evidence-based guidelines into both practice and research, the Research and Development Committee of the International Urogynecological Association embarked on a lengthy process, which included a literature review, creation of recommendations, incorporation of expert consultant opinion, writing a white paper for association members, final revision, and then publication in its journal.
-
The primary objective of the PLCO study is to evaluate the impact of annual screening with transvaginal ultrasound (TVUS) and CA125 on ovarian cancer mortality. The study is prospectively following a cohort of more than 34,000 largely postmenopausal women with intact ovaries with an algorithm where either an abnormal CA125 (e" 35 units/mL) or an abnormality on TVUS is considered a positive screen.
-
Your next patient is an adolescent female who has requested immunization with the vaccine for human papillomavirus (HPV). When she asks specifically about the vaccine's safety, what can you tell her?
-
The next patient in your exam room is a 17-year-old female who uses the contraceptive injection depot medroxyprogesterone acetate (DMPA) for birth control.
-
Research findings presented at a February 2009 international conference indicate that an investigational gel known as PRO 2000 (Indevus Pharmaceuticals; Lexington, MA) proved about 30% effective in preventing HIV infection in women.